D46.22 Refractory anemia with excess of blasts 2

Name of the Condition

• Refractory anemia with excess of blasts 2

Summary

Refractory anemia with excess of blasts 2 (RAEB-2) is a subtype of myelodysplastic syndrome (MDS) characterized by ineffective blood cell production in the bone marrow, leading to low blood cell counts (cytopenias) and abnormal cell development. The condition is termed "refractory" because it does not respond to standard treatments for anemia. RAEB-2 is distinguished by the presence of an increased number of immature blood cells (blasts) in the bone marrow and blood, and it carries a higher risk of progressing to acute myeloid leukemia (AML) compared to other MDS subtypes.

Causes

The exact cause of RAEB-2 is often unknown. It may involve genetic mutations that disrupt normal blood cell production. Other factors can include previous chemotherapy or radiation therapy, exposure to certain chemicals (e.g., benzene), and rarely, inherited bone marrow failure syndromes.

Risk Factors

• Age (most common in individuals over 60)
• Previous cancer treatment with chemotherapy or radiation
• Exposure to industrial chemicals like benzene
• Family history of MDS or other blood disorders
• Certain genetic conditions (e.g., Fanconi anemia)

Symptoms

• Fatigue or weakness
• Frequent infections
• Easy or unexplained bruising or bleeding
• Shortness of breath
• Pale skin
• Unexplained weight loss

Diagnosis

Diagnosis involves a combination of blood tests to assess cell counts and morphology, bone marrow aspiration and biopsy to evaluate blast percentage and cell abnormalities, and cytogenetic analysis to detect chromosomal changes. Additional tests may include flow cytometry or molecular studies to identify genetic mutations.

Treatment Options

Treatment focuses on managing symptoms and reducing complications. Options may include blood transfusions, growth factors to stimulate blood cell production, chemotherapy (e.g., hypomethylating agents), and in some cases, stem cell transplantation. Supportive care, such as antibiotics for infections or medications to control bleeding, is also common.

Prognosis and Follow-Up

RAEB-2 has a higher risk of progressing to AML compared to other MDS subtypes. Prognosis depends on factors like blast percentage, cytogenetic findings, and overall health. Regular monitoring with blood tests and bone marrow evaluations is essential to track disease progression and adjust treatment.

Complications

• Progression to acute myeloid leukemia (AML)
• Severe anemia leading to fatigue or heart problems
• Increased risk of infections due to low white blood cell counts
• Bleeding disorders from low platelet counts
• Organ damage from chronic anemia or transfusion-related iron overload

Lifestyle & Prevention

• Avoid exposure to chemicals like benzene
• Maintain a balanced diet to support overall health
• Practice good hygiene to reduce infection risk
• Follow up regularly with healthcare providers for monitoring
• Discuss any previous cancer treatments with your doctor, as they may increase risk

When to Seek Professional Help

Seek immediate medical attention if you experience severe fatigue, uncontrolled bleeding, high fever, or shortness of breath. Regular check-ups are important for those with known risk factors or diagnosed MDS to monitor for changes in symptoms or blood counts.

Tips for Medical Coders

Document the specific blast percentage in the bone marrow or blood, as this distinguishes RAEB-2 from other MDS subtypes. Ensure clinical notes support the diagnosis, including any cytogenetic or molecular findings. Verify that the code aligns with the documented blast count and disease classification.